Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing ...

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 3 September 2026 · Fusion42 review

AbbVie announced positive Phase 3 CERVINO trial results for etentamig, a BCMA x CD3 bispecific T-cell engager, showing significantly improved response rate and progression-free survival in patients with relapsed/refractory multiple myeloma compared to standard therapies, with a manageable safety profile enabling outpatient use.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech company must rethink patient access as etentamig’s safety and dosing enable multiple myeloma treatment outside specialist centres. This shifts commercial and clinical strategies towards community-based care and outpatient models.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Biotechmultiple-myelomabcmabispecific-t-cell-engagerclinical-trialoncologyoutpatient-treatment